NCT07158229 Long-term Impact of NMDAR Encephalitis, Level 3
| NCT ID | NCT07158229 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | NMDAR Autoimmune Encephalitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-11-21 |
| Primary Completion | 2026-11-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2025-11-21 with a primary completion date of 2026-11-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored. Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.
Eligibility Criteria
Inclusion Criteria: * Patients with NMDAR encephalitis * Age ≥ 18 years old * Patient affiliated to a social security system * No opposition from the patient * Access to an internet connection and a computer Exclusion Criteria: * Patients whithout NMDAR encephalitis * Patient under guardianship or curatorship * Patient with neurological disorders pre-existing encephalitis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07158229 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NMDAR Autoimmune Encephalitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07158229 currently recruiting?
Yes, NCT07158229 is actively recruiting participants. Contact the research team at jerome.honnorat@chu-lyon.fr for enrollment information.
Where is the NCT07158229 trial being conducted?
This trial is being conducted at Bron, France.
Who is sponsoring the NCT07158229 clinical trial?
NCT07158229 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 30 participants.